Aclaris Therapeutics, Inc. Accumulated Other Comprehensive Income
Aclaris Therapeutics, Inc. (ACRS) had Accumulated Other Comprehensive Income of -$304.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$304.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $22.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $610.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $597.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$304.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $22.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $610.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $597.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $482.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $434.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $97.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $427.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$463.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$364.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$106.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | -$1.13M 10-Q · filed 2023-11-06 |
| 2023-06-30 | -$1.11M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$354.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$897.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$1.47M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$1.33M 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$972.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$224.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | -$3.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | -$184.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$140.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | -$94.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | -$44.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $15.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $47.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$66.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | -$1.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $8.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | -$49.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$69.00K 10-K · filed 2020-02-25 |
| 2018-09-30 | -$116.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$188.00K 10-Q · filed 2018-08-03 |
| 2018-03-31 | -$328.00K 10-Q · filed 2018-05-08 |
| 2017-12-31 | -$246.00K 10-K · filed 2019-03-18 |
| 2017-09-30 | -$113.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$166.00K 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$249.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$269.00K 10-K · filed 2018-03-12 |
| 2016-09-30 | -$54.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $1.00K 10-Q · filed 2016-08-11 |
| 2016-03-31 | $3.00K 10-Q · filed 2016-05-11 |
| 2015-12-31 | -$149.00K 10-K · filed 2017-03-15 |
| 2015-09-30 | $1.00K 10-Q · filed 2015-12-03 |
| 2014-12-31 | -$6.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |